Loading organizations...
§ Venture Capital · New York City, NY, USA
Information on this organization's business model, services, and market focus is not publicly available at this time.
Key people at Althea Group Ventures.
Althea Group Ventures is a European operator providing integrated clinical engineering services and biomedical technology management for hospitals, based in Milan, Italy. The company focuses on the technological modernization of medical infrastructure through extended service contracts with public and private healthcare entities across the continent. In May 2022, the organization was acquired by the infrastructure fund F2i SGR, while its United Kingdom operations were concurrently separated and sold to DWS. This strategic transition shifted the firm's primary financial backing from the private equity firm Permira to F2i SGR, an institutional investor managing over €6 billion in assets under management. The business generates revenue by maintaining and optimizing complex hospital equipment portfolios. While the exact founding year and original founders remain undisclosed, the enterprise is currently led by Chief Executive Officer Alessandro Dogliani and Chief Operating Officer Massimo Sala.
Key people at Althea Group Ventures.
Althea Group Ventures has 2 tracked investments across 2 companies. The latest tracked deal is $1.9M Seed in Hera Biotech in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 24, 2022 | Hera Biotech | $1.9M Seed | — | Coyote Ventures, Lesley Robinson, Stella Angels |
| May 27, 2021 | Oisin Biotechnologies | $5.0M Seed | Althea Group Ventures | — |
Althea Group Ventures is an early-stage venture capital and strategic advisory firm specializing in genetic medicine and biotechnology startups, particularly those developing delivery technologies for nucleic acid therapeutics. Their mission centers on supporting innovative biotech companies with growth capital and strategic guidance to accelerate the development of next-generation genetic medicines, including breakthrough gene delivery platforms and targeted cancer therapies. They focus primarily on pre-seed and seed-stage investments within the USA and Canada, emphasizing sectors such as biotechnology, health tech, and AI. By backing disruptive early-stage companies, Althea Group plays a significant role in advancing the biotech startup ecosystem, fostering innovation in genetic medicine and related health technologies[1][2][4].
Founded with a focus on early-stage investments in genetic medicine, Althea Group has evolved into a venture capital firm and strategic advisor that leverages a global network spanning finance, academia, and industry. The firm’s leadership has extensive experience backing over 50 startups across technology and healthcare sectors in Asia and North America, with a hands-on, operator-centric approach that enhances value creation. This background informs their focus on high-potential biotech startups, particularly those developing novel nucleic acid delivery technologies and gene therapies. Their evolution reflects a deepening specialization in genetic medicine and strategic advisory services tailored to early-stage companies[1][3][4].
Althea Group Ventures rides the wave of rapid advancements in genetic medicine and biotechnology, sectors experiencing transformative innovation due to breakthroughs in gene editing, nucleic acid therapeutics, and personalized medicine. The timing is critical as demand for safer, more effective gene delivery technologies grows alongside increasing regulatory acceptance and scientific validation. Market forces such as rising healthcare costs, aging populations, and the need for targeted therapies favor investment in biotech innovation. Althea’s strategic advisory and capital support help bridge the gap between early scientific discovery and commercial viability, influencing the broader ecosystem by enabling startups to translate cutting-edge research into impactful therapies[1][4].
Looking ahead, Althea Group Ventures is well-positioned to capitalize on the expanding genetic medicine market by continuing to invest in pioneering delivery technologies and therapeutic platforms. Trends such as AI integration in biotech, personalized medicine, and remote health monitoring will likely shape their investment focus. Their influence may grow as they deepen their strategic advisory capabilities and expand their portfolio, potentially driving more breakthroughs in gene therapy and related fields. This trajectory aligns with their mission to accelerate the development of transformative genetic medicines, reinforcing their role as a key enabler in the biotech startup ecosystem[1][4].
